Stroke recovery in rats after 24h-delayed intramuscular neurotrophin-3 infusion by Duricki, D.A. et al.
RESEARCH ARTICLE
Stroke Recovery in Rats after
24-Hour–Delayed Intramuscular
Neurotrophin-3 Infusion
Denise A. Duricki, PhD,1,2 Svetlana Drndarski, PhD,3 Michel Bernanos, PhD,4
Tobias Wood, PhD,4 Karen Bosch, PhD,1 Qin Chen, PhD,5 H. David Shine, PhD,5
Camilla Simmons, PhD,4 Steven C. R. Williams, PhD,4 Stephen B. McMahon, PhD,1
David J. Begley, PhD,3 Diana Cash, PhD,4 and Lawrence D. F. Moon, PhD 1,2
Objective: Neurotrophin-3 (NT3) plays a key role in the development and function of locomotor circuits including
descending serotonergic and corticospinal tract axons and afferents from muscle and skin. We have previously shown
that gene therapy delivery of human NT3 into affected forelimb muscles improves sensorimotor recovery after stroke
in adult and elderly rats. Here, to move toward the clinic, we tested the hypothesis that intramuscular infusion of NT3
protein could improve sensorimotor recovery after stroke.
Methods: Rats received unilateral ischemic stroke in sensorimotor cortex. To simulate a clinically feasible time to treat-
ment, 24 hours later rats were randomized to receive NT3 or vehicle by infusion into affected triceps brachii for 4 weeks
using implanted catheters and minipumps.
Results: Radiolabeled NT3 crossed from the bloodstream into the brain and spinal cord in rodents with or without
strokes. NT3 increased the accuracy of forelimb placement during walking on a horizontal ladder and increased use of
the affected arm for lateral support during rearing. NT3 also reversed sensory impairment of the affected wrist. Func-
tional magnetic resonance imaging during stimulation of the affected wrist showed spontaneous recovery of peri-
infarct blood oxygenation level–dependent signal that NT3 did not further enhance. Rather, NT3 induced neuroplasti-
city of the spared corticospinal and serotonergic pathways.
Interpretation: Our results show that delayed, peripheral infusion of NT3 can improve sensorimotor function after
ischemic stroke. Phase I and II clinical trials of NT3 (for constipation and neuropathy) have shown that peripheral high
doses are safe and well tolerated, which paves the way for NT3 as a therapy for stroke.
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Ischemic stroke occurs in the brain when blood flow isrestricted, causing brain cells to die rapidly. Worldwide,
there are an estimated 31 million stroke survivors, with
another 9 million new strokes annually. Therapies that
reverse impairments are urgently needed.1
Neurotrophin-3 (NT3) is a growth factor that plays a
key role in the development and function of locomotor cir-
cuits, including descending serotonergic2 and corticospinal
tract (CST) axons3 and afferents from muscle and skin that
mediate proprioception and tactile sensation.4–6 However,
levels of NT3 drop in the postnatal period.7 We and others
have shown that delivery of NT3 into the central nervous sys-
tem (CNS) promotes recovery in models of spinal cord
injury,8–15 but this involved invasive routes of delivery or gene
therapy. We also recently showed that injection of an adeno-
associated viral vector (AAV) encoding full-length human
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NT3 (preproNT3, 30 kDa) into forelimb muscles 24 hours
after stroke in adult or elderly rats in adult rats improved CST
sprouting and sensorimotor recovery.16 We had originally
expected that AAV1 would be trafficked from muscle to the
spinal cord retrogradely in axons17 and that enhanced secre-
tion of NT3 by motor neurons would lead to sprouting of the
spared CST9,18,19 and sensorimotor recovery. However,
although NT3 protein was overexpressed in injected muscles,
to our surprise we found little evidence for expression of the
human NT3 transgene in the spinal cord or cervical dorsal
root ganglia (DRGs)14,16 using this modest dose of AAV. This
serendipitous result led us to reject our original assumption
that sensorimotor recovery required expression of the human
NT3 transgene in the spinal cord and to wonder whether
intramuscular infusion of NT3 protein would suffice.
Accordingly, here, we tested the hypothesis that infu-
sion of NT3 protein (14 kDa) into impaired forelimb mus-
cles would improve sensorimotor recovery after stroke (ie,
bypassing the need for gene therapy and spinal surgery).
This is plausible because others have shown that a signal
from muscle spindles can improve neuroplasticity of des-
cending pathways and can enhance recovery after spinal
cord lateral hemisection.20 Notably, NT3 protein is synthe-
sized by muscle spindles21 and NT3 can be transported
from muscle to sensory ganglia and spinal motor neurons
in nerves6,14,16 as well as to the CNS and peripheral ner-
vous system (PNS) via the bloodstream.22–24 Importantly,
NT3 protein has excellent translational potential; phase I
and II clinical trials have shown that repeated, systemic
high doses of NT3 protein are well tolerated, safe, and
effective in >200 humans with sensory and motor neuropa-
thy (Charcot–Marie–Tooth type 1A)25 or constipation
including in people with spinal cord injury.25,26 These
studies pave the way for NT3 as a therapy for stroke in
humans. We now show in a blinded, randomized preclini-
cal trial that treatment of impaired upper arm muscles with
human NT3 protein reverses sensory and motor disability
in rats when treatment is initiated in a clinically feasible
timeframe (24 hours after stroke).
Materials and Methods
Full methodological details are available online.27
Experimental Design
All surgical procedures and behavioral testing were performed
using a randomized block design with experimenters and princi-
pal investigator blinded to treatment groups by a third party.27
All procedures were in accordance with the Animals (Scientific
Procedures) Act of 1986. All protocols involving animals received
prior approval by the King’s College London Animal Welfare
Ethical Review Board and were authorized by the UK Home
Office Project (license number 70/7865, held by L.D.F.M.).
Stroke or Sham Lesions
Sixty Lister Hooded outbred female rats (~4 months old,
200–300 g, Charles River, Wilmington, MA) received focal ische-
mic stroke in the sensorimotor cortex representing the dominant
forelimb (Fig 1), defined by the cylinder test, as described for
elderly rats16 (see Fig 1A, B) with minor modifications as
described in detail elsewhere.27 Briefly, anesthetized animals were
transferred to a stereotaxic frame where a midline incision was
made, the cortex was then exposed via craniotomy using the fol-
lowing coordinates (defined as anteroposterior [AP] and mediolat-
eral [ML]): AP 4 mm to −2 mm, ML 2 mm to 4 mm, relative to
bregma. Endothelin-1 (ET-1; 400 pmol/μl in sterile saline; Cal-
biochem, San Diego, CA) was applied using a glass micropipette
attached to a Hamilton syringe. One microliter of ET-1 was
applied to the overlying dura to reduce bleeding, and immediately
thereafter, the dura mater was incised and reflected. Four 1 μl vol-
umes of ET-1 were administered topically, and four 1 μl volumes
were microinjected intracortically (at a depth of 1 mm from the
brain surface) at the following coordinates (from bregma and mid-
line, respectively): (1) AP 3.5 mm, ML 2.8 mm; (2) AP 2.0 mm,
ML 2.8 mm; (3) AP 0.5 mm, ML 2.8 mm; and (4) AP
−1.0 mm, ML 2.8 mm. Temperature was maintained using a rec-
tal probe connected to a homeothermic blanket (Harvard Appara-
tus, Holliston, MA) placed under the animal, which maintained
rectal temperature at 36  1C. Prior to suturing, the animal was
left undisturbed for 5 minutes. The skull fragment was then
replaced and sealed using bone wax (Covidien, Gosport, UK). Five
sham-operated rats received all procedures excluding craniotomy.
All rats survived this surgery. Animals were given buprenorphine
(0.01 mg/kg, subcutaneously).
Structural and Functional Magnetic Resonance
Imaging
Structural magnetic resonance imaging (MRI) images were obtained
prior to stroke, 24 hours after stroke, and at 1 and 8 weeks after
stroke as described with full details elsewhere.16,27 Functional MRI
(fMRI) was performed prior to stroke and at 1 and 8 weeks after
stroke during non-noxious stimulation of the affected wrist as
described fully elsewhere27 in a subset of rats that did not receive
intracortical injections of biotinylated dextran amine (BDA) tracer
(n = 10/group). Two animals died following alpha chloralose anes-
thesia due to breathing difficulties in recovery.
NT3 or Vehicle Treatment
Twenty-four hours after stroke (immediately after MRI), rats
were randomized to treatment using NT3 or vehicle, infused
into affected triceps brachii muscles for 1 month via thin, flexible
implanted catheters and subcutaneous osmotic minipumps
(2ML2; Alzet, Cupertino, CA; 5 μl/h flow rate, 2 ml reservoir)
compatible with MRI.27 Full technical details have been pro-
vided elsewhere.27 Treatments were vehicle (0.9% saline contain-
ing 0.1% bovine serum albumin; Sigma, St Louis, MO; A3059;
9048-46-8) or vehicle containing recombinant human NT3
(100 μg/ml; gift of Genentech, South San Francisco, CA).
Pumps were replaced after 2 weeks and removed after 4 weeks.
Skin was sutured and analgesic was administered as above. All
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rats survived this surgery. Pilot experiments showed that the
pump flow rate (5 μl/h) was sufficient to deliver substances
(0.9% saline containing 1% Fast Green, Sigma) to the entire vol-
ume of the triceps muscles. The identity of this preparation of
NT3 was confirmed to consist of the ~14 kDa monomer and
~28 kDa dimer by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and liquid chromatography–mass spectrometry.27
The NT3 dose (12 μg per 24 hours) was selected based on previ-
ous experiments.28
Enzyme-Linked Immunosorbent Assay
A random subset of rats (n = 5/group) were anesthetized (4 weeks
following stroke, before pumps were removed) and triceps bra-
chii and C7 spinal cord were rapidly dissected and snap frozen in
FIGURE 1: Focal stroke caused unilateral infarction in sensorimotor cortex, resulting in a loss of corticospinal axons. (A, B) Rats
received sham surgery (n = 5) or unilateral cortical stroke, and 24 hours later infusion of neurotrophin-3 (NT3; n = 30) or vehicle
(Veh; n = 30) into the affected triceps brachii was initiated for 1 month. Six weeks after stroke, anterograde tracer was injected
into the contralesional sensorimotor cortex. Rats underwent 8 weeks of behavioral testing. Structural magnetic resonance
imaging (MRI) was conducted on all rats at 24 hours, 1 week, and 8 weeks after stroke and functional MRI (fMRI) was conducted
in a subset of rats at baseline, week 1, and week 8. Electrophysiology was performed in the subset of rats that did not receive
biotinylated dextran amine (BDA) tracing. All surgeries, treatments, and behavioral testing were performed using a randomized
block design, and the study was completed blinded to treatment allocation. (C) T2 MRI scans 24 hours after stroke, immediately
prior to treatment, showing infarct in coronal sections rostral (numbers represent millimeters) to bregma. (D) There were no
differences between stroke groups in mean lesion volume at 24 hours (Mann–Whitney p value = 0.86). (E) Photomicrographs
showing loss of corticospinal tract (CST) axons in the upper cervical dorsal columns 8 weeks after stroke (right) relative to sham
surgery (left), visualized using protein kinase C gamma (PKC-γ) immunofluorescence. ***p ≤ 0.001. (F) Stroke caused a significant
loss of CST axons relative to shams (Kruskal–Wallis χ2 = 12.0, p = 0.002; Mann–Whitney p values <0.001), with no differences
between vehicle-treated and NT3-treated rats (Mann–Whitney p = 0.96). Representative images of 1 stroke and 1 sham animal
are shown. Panel B is modified from Duricki et al16 with permission. ELISA = enzyme-linked immunosorbent assay; NS = not
significant. [Color figure can be viewed at www.annalsofneurology.org]
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liquid nitrogen prior to storage at −80C. Tissue was homoge-
nized in ice-cold lysis buffer containing 137 mM NaCl, 20 mM
Tris-HCl (pH 8.0), 1% NP40, 10% glycerol, 1 mM phenyl-
methanesulfonylfluoride, 10 μg/ml aprotinin, 1 μg/ml leupeptin,
and 0.5 mM sodium vanadate, using 10 μl buffer per milligram
of tissue. Protein content was measured and NT3 enzyme-linked
immunosorbent assay (ELISA) was carried out according to man-
ufacturers’ instructions (Emax; Promega, Madison, WI). Full
details have been given elsewhere.27
Behavioral Testing
Rats were handled and trained for 3 weeks on the horizontal lad-
der before the study began. Preoperative baseline scores for the
horizontal ladder, the vertical cylinder, and the grip strength test
were collected 1 week before surgery.
Assessment of Somatosensory Responsiveness. The “adhe-
sive patch” test was used to measure (1) the time taken to
contact stimuli on the wrists, (2) the time taken to remove
stimuli from the wrists, and (3) the magnitude of lack of
responsiveness to stimuli on the affected wrist as previ-
ously described.16,27 To determine whether the rats prefer-
entially removed a sticker from their less-affected wrist
before their more-affected wrist, the order and side of label
removal was recorded. This was repeated 4 times per ses-
sion until a > 75% preference had been found; if this was
not the case, a fifth trial was conducted. The magnitude
of asymmetry was established using the 7 levels of stimu-
lus pairs on both wrists as previously described (Fig 2A).
From trial to trial, the size of the stimulus was progres-
sively increased on the affected wrist and decreased on the
less affected wrist by an equal amount (14.1mm2), until
the rat removed the stimulus on the affected wrist first
(reversal of original bias). The higher the score, the greater
the degree of somatosensory impairment.
Walking. To assess impairments in forelimb and hin-
dlimb function after stroke, rats were videotaped as they
walked along a horizontal ladder.16,27 Rats were video-
taped crossing a horizontal ladder (1 m) with irregularly
spaced rungs weekly, 3 times per session. Any slight paw
slips, deep paw slips, and complete misses were scored as
an error. The mean number of errors per step was calcu-
lated for each limb for each week.
Assessment of Forelimb Use During Rearing. The cylinder
test was used to assess asymmetries in forelimb use for
postural support during rearing within a transparent
20 cm-diameter and 30 cm-high cylinder.16,27 An angled
mirror was placed behind the cylinder to allow movements
to be recorded when the animal turned away from the
camera. During exploration, rats rear against the vertical
surface of the cylinder. The first forelimb to touch the
wall was scored as an independent placement for that fore-
limb. Subsequent placement of the other forelimb against
the wall to maintain balance was scored as “both.” If both
forelimbs were simultaneously placed against the wall dur-
ing rearing, this was scored as “both.” A lateral movement
along the wall using both forelimbs alternately was also
scored as “both.” Scores were obtained from a total num-
ber of 10 full rears to control for differences in rearing
between animals. Once scores had been acquired, forelimb
asymmetry was calculated using the formula: 100 × (ipsilat-
eral forelimb use +1/2 bilateral forelimb use) / total fore-
limb use observations.
Anatomical Tracing
To visualize uninjured CST axons, 6 weeks after stroke, 10%
BDA in phosphate-buffered saline (PBS; pH 7.4) was microin-
jected unilaterally into the uninjured sensorimotor cortex as
described previously.16,27 Briefly, animals were placed in a stereo-
taxic frame and 6 burr holes were made into the skull at the fol-
lowing coordinates: (1) AP 1 mm, ML 1.5 mm; (2) AP 0.5 mm,
ML 2.5 mm; (3) AP 1.5 mm, ML 2.5 mm; (4) AP 0.5 mm, ML
3.5 mm; (5) AP 2.0 mm, ML 3.5 mm; and (6) AP − 0.5 mm,
ML 3.5 mm, relative to bregma. At each site, 0.5 μl injections of
BDA (10% in PBS) were delivered using a glass micropipette
attached to a Hamilton syringe inserted 2 mm from the skull sur-
face and delivered at a rate of 0.25 μl/min. Animals were left for
2 weeks before being perfused. Tract tracing was not performed in
rats that were to undergo fMRI or neurophysiology.
Neurophysiology
We recorded from the ulnar nerve on the affected side and stim-
ulated, in the pyramids, the CST corresponding to the affected
or less-affected hemisphere, as described previously.27 At the end
of the study, 18 rats (6 rats per group) were anesthetized with an
intraperitoneal injection of 1.25 g/kg urethane (Sigma-Aldrich,
St Louis, MO). The rats were kept at 37C with a homeother-
mic blanket system and rectal thermometer probe. Tracheotomy
was performed, and a tracheal cannula was inserted. The pyra-
mids were then exposed ventrally by blunt dissection and
removal of a small area of bone. The brachial plexus of the
affected forelimb was exposed from a ventral approach by dissect-
ing the pectoralis major. The ulnar and median nerves were dis-
sected free from surrounding connective tissue and cut distally
(to prevent twitches of target muscles). Skin flaps from the inci-
sion formed a pool, which was filled with paraffin oil. The proxi-
mal segment of the ulnar nerve was mounted on a pair of silver
wire hook electrodes (with >1 cm separation). The concentric
bipolar stimulation electrode (CBBPC75; FHC, Bowdoin, ME)
was located 1 mm lateral to the midline and gently lowered
through the pyramid up to a maximum depth of 1.5 mm while
stimulating at 300 μA (4 pulses, square wave pulse width = 100
microseconds, frequency = 500 Hz). At the electrode location
providing maximal ulnar nerve response, stimuli of increasing
intensity were applied in the range of 50 to 400 μA, in 50 μA
increments. Five sweeps were captured at each stimulus intensity.
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FIGURE 2: Delayed neurotrophin-3 (NT3) treatment improved responsiveness to somatosensory stimulation, improved walking, and
partially restored use of the affected forelimb for lateral support during rearing. (A) Somatosensory deficits were assessed using pairs of
adhesive patches attached to the rat’s wrists. (B) Treatment with NT3 caused improvement compared to vehicle (linear model; F2,
126 = 32.5, p < 0.001; post hoc p = 0.003), whereas vehicle-treated stroke rats showed a deficit relative to sham rats that persisted for
8 weeks (linear model; F14, 263 = 4.1, p < 0.001; post hoc p values <0.02). NT3 caused improvements such that by 6 weeks they had
recovered fully relative to shams (post hoc p values >0.4) and to vehicle-treated stroke rats (post hoc p values <0.001). There were no
differences between NT3-treated and vehicle-treated rats at 1 week (t test p = 0.33). BL = baseline. (C) Accuracy of paw placement by
the affected forelimb during walking was assessed using a horizontal ladder with irregularly spaced runs. (D) One week after stroke,
NT3-treated and vehicle-treated rats made a similar number of misplaced steps with their affected forelimb (t test p = 0.78), expressed
as a percentage of total steps by that limb. Importantly, the NT3 group progressively recovered compared to the vehicle group (group
F2, 52 = 17.0, p < 0.001; post hoc p = 0.008) and differed from the vehicle group from weeks 5 to 8 (group × time F14, 355 = 6.2,
p < 0.001; post hoc p values <0.005); whereas the vehicle group remained impaired relative to shams from weeks 5 to 8 (p values
<0.006), from weeks 5 to 8 the NT3 group made nearly as few errors as shams (post hoc p values >0.05). (E) The vertical cylinder test
assessed use of the affected forelimb for lateral support during rearing. (F) Stroke caused a reduction in the use of the affected forelimb
during rearing in a vertical cylinder in both NT3-treated and vehicle-treated rats relative to shams (group F2, 56 = 6.1, p = 0.004; post hoc
p values = 0.001 and 0.003, respectively) with no differences between stroke groups at 1 week (p = 0.52). NT3 treatment caused a
progressive recovery in the use of the affected forelimb (group × wave F14, 356 = 1.78, p = 0.04) by weeks 7 and 8 relative to vehicle-
treated rats (p values = 0.015 and 0.067, respectively). Sham group, n = 5; stroke and NT3 group, n = 29; stroke and vehicle group,
n = 28. Sham rats are represented by circles with dashed lines, NT3 stroke rats are represented by triangles with solid lines, and vehicle
stroke rats are represented by squares with dotted lines. [Color figure can be viewed at www.annalsofneurology.org]
The signal was rectified, and the area under the curve was mea-
sured between 17 and 45 milliseconds. Data were analyzed using
2-way repeated measures analysis of variance (ANOVA). Graphs
show mean and standard error of the mean for the area under
the curve for stimuli given at 400 μA.
Histology
Eight weeks after stroke surgery and 2 weeks after injection of
BDA, rats were terminally anesthetized with sodium pentobarbital
(80 mg/kg intraperitoneal) and perfused with PBS for 5 minutes,
followed by 500 ml of 4% paraformaldehyde in PBS for
15 minutes. The brain, C6–C8 spinal cord, C7 and C8 DRGs,
and both arms were carefully dissected and stored in 4% parafor-
maldehyde in PBS for 2 hours and then transferred to 30%
sucrose in PBS and stored at 2 to 5C. Spinal cord segments C1
and C7 was embedded in OCT and 40 μm transverse slices were
cut using a freezing stage microtome. Ten series of sections were
collected.
Series of 40 μm-thick transverse sections of fixed spinal cord
were immunolabeled as previously described.16,27 Primary antibodies
(overnight) were rabbit anti–protein kinase C gamma (PKCγ; 1:500,
sc-211; Santa Cruz Biotechnology, Santa Cruz, CA) and rabbit anti-
serotonin (1:6,000, #20080; ImmunoStar, Hudson, WI). Secondary
antibodies (3 hours) were: goat antirabbit IgG Alexa 488 (1:1,000;
Invitrogen, Carlsbad, CA) with DAPI (1:50,000, Sigma).
BDA staining was performed as described before.16,27
CST axons were counted that crossed the midline, at 2 more lat-
eral planes and at an oblique plane (Fig 3A) on the affected side
at C7 and C1. For each rat, we estimated the number of CST
axons per cord segment by calculating the average number of
CST axons per section and then multiplying by a scaling factor
(number of sections per segment).
The total length of serotonergic processes was measured
using a method14 that is well suited for quantification of dense
terminal arbors. Processes were identified using the “adjust
threshold” function in ImageJ, and fiber lengths were measured
in 3 areas: the dorsal horn, intermediate horn, and ventral horn
(Fig 4B) in 3 sections per rat. We calculated the ratio of the sides
ipsilateral and contralateral to treatment for the 3 areas
separately.
Immunofluorescence was visualized under a Zeiss
(Oberkochen, Germany) Imager.Z1 microscope or a confocal
Zeiss LSM 700 laser scanning microscope. Photographs were
taken using the AxioCam and AxioVision LE Rel. 4.2 or LSM
Image Browser software for image analysis.
Radiolabeling of NT3
NT3 protein was radiolabeled with 50 μCi (1.85 MBq) N-
succinimidyl [2,3-3H]propionate (3H-NSP) and separated from
unbound 3H-NSP using an ÄKTAprime (GE Healthcare, Chi-
cago, IL) purification system using a modification of a previous
method.29 Fifty micrograms of [3H]NT3 or [3H]albumin was
injected intravenously as a 300 μl bolus into 95 adult C57Bl/6
mice (7–8 weeks old). This method had been optimized for
mice. After 3, 15, 20, 30, 40, 60, or 90 minutes, brain, spinal
cord, and serum were taken for scintillation counting. The rate
of influx was calculated from the Patlak plot30 of the distribution
volume (VD) for [
3H]NT3 and [3H]albumin against the plasma
area under the curve.
The same treatment was repeated for mice 24 hours after
stroke, with an incubation period of 40 minutes (n = 6). 14C
sucrose (0.074 MBq; vascular marker) was injected toward the
end of the incubation, and the brain tissue was taken for capil-
lary depletion analysis. Brain tissue was homogenized in physio-
logical buffer (30 μl/mg of tissue) and 26% dextran (40 μl/mg of
tissue) as described previously.31 The homogenate was subjected
to density gradient centrifugation (5,400 × g for 15 minutes at
4C) to give an endothelial cell-enriched pellet and a fraction
containing the brain parenchyma and interstitial fluid. The sam-
ples were solubilized and counted as described above. VD was
calculated. The values were corrected for 14C sucrose. Data were
analyzed for capillary fraction, parenchymal fraction, and whole
brain using 1-way ANOVA and Bonferroni t tests.
Statistics
A set of a priori sample size calculations were performed and
reported previously for this ET-1 model and for 4 behavioral
tests (Montoya staircase test, adhesive patch test, cylinder test,
horizontal ladder; see Methods and Table 1 in Soleman et al32).
G*Power 3.1 was used to estimate the effect size of the differ-
ence between the stroke and sham groups for each behavioral test
using the post hoc algorithm for F tests (repeated measures,
between factors). Next, G*Power was used33 to estimate the
minimum sample sizes that would be required in experiments
(using 2 groups) to identify treatment effects of 3 different mag-
nitudes (25% recovery, 50% recovery, 75% recovery) using the
a priori algorithm for F tests (repeated measures, between factors)
using the following parameters: type I error threshold (α) ≤ 0.05
and power (1 − β) ≥ 0.80. The “correlation between repeated
measures” parameter was derived by calculating the mean of the
Pearson product-moment correlation coefficients for each of all
possible (6) pairs of (4) time points in that study.32 In the pre-
sent study, we chose n = 30 for the NT3 and vehicle groups to
increase our chances of detecting small improvements in sensori-
motor function based on these a priori power calculations. We
knew from previous work using NT3 what typical effect sizes
could be expected in this model.16
Statistical analyses were conducted using SPSS (v18.0;
IBM, Armonk, NY). Graphs show means  standard error of
the mean, and n denotes number of rats or mice. The threshold
for significance was 0.05. Corticospinal tract sprouting data were
analyzed using 1-way ANOVA per plane and unpaired t tests.
Serotonergic fiber lengths were analyzed by region using 1-way
ANOVA and Bonferroni post hoc tests. Other histology and
molecular biology data were assessed using Kruskal–Wallis and
Mann–Whitney tests. Behavioral data were analyzed using linear
models and restricted maximum likelihood estimation to accom-
modate data from rats with occasional missing values (using
SPSS MIXED with Fisher least squares difference post hoc tests
as described previously34). Baseline scores were used as covari-
ates. Post hoc p values were only reported when the preceding
global (protected) test (eg, factorial linear models, 1-way
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FIGURE 3: Delayed neurotrophin-3 (NT3) treatment caused corticospinal tract (CST) sprouting and increased output in forelimb
motor nerves during CST stimulation. (A) Corticospinal axons were anterogradely traced from the less-affected cortex and were
counted at the midline (M), at 2 more lateral planes (D1 and D2), and crossing into gray matter from the ipsilateral, ventral tract
(Ipsi). (B) NT3 treatment caused an increase in the number of axons crossing at the midline (F2, 28 = 6.1, p = 0.007; post hoc
p value = 0.003), at 2 lateral planes denoted as D1 (F2, 28 = 20.3, p < 0.001, post hoc p value<0.001) and D2 (F2, 28 = 13.8,
p < 0.001, post hoc p value<0.001), and from the ventral CST on the treated side (F2, 28 = 5.2, p = 0.013; post hoc
p value = 0.005). Ten rats per group were used for tract tracing. (C–E) The CST from the less-affected hemisphere or (F–H) lesioned
hemisphere was stimulated in the medullary pyramids (before the decussation) and the motor output was recorded from the ulnar
nerve on the treated side. (D, G) The majority of spikes were detected between 17 and 45 milliseconds, latencies consistent with
polysynaptic transmission, in both vehicle-treated rats (top trace in D and G) and NT3-treated rats (bottom trace in D and G) when
the less-affected or affected CST was stimulated. (E, H) Stimulus intensity was increased incrementally from 50 to 400 μA and the
area under the curve were measured (between 17 and 45 milliseconds) after stimulation of the affected or less-affected CST. NT3
treatment caused increased output in the ulnar nerve during stimulation of either the affected CST (2-way repeated measures
analysis of variance intensity × group interaction F1, 14 = 7.9, p = 0.008, n = 6 vehicle, n = 6 NT3) or less-affected CST (F2, 17 = 9.8,
p = 0.01, n = 4 vehicle, n = 6 NT3). *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. REC = recording; STIM = stimulating; Veh = vehicle.
Panels A, C, and F were modified from reference 16 with permission. [Color figure can be viewed at www.annalsofneurology.org]
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ANOVAs, or Kruskal–Wallis tests) was significant for the main
effect or interaction term (p < 0.05). For transparency, post hoc
p values are stated exactly (or when small, as p < 0.001, for
example). Degrees of freedom are reported to the nearest integer.
Normality was assessed using histograms. Tests were 2-tailed.
Results
MRI Confirmed Equivalent Infarct Volumes
between Stroke Groups
MRI confirmed that infarcts included the forelimb and
hindlimb areas in sensorimotor cortex (see Fig 1). There
was no difference in the mean infarct volume between
stroke groups at 24 hours or 1 or 8 weeks after stroke.
Loss of CST axons was assessed at 8 weeks in the upper
cervical spinal cord using PKCγ immunofluorescence.35,36
Stroke caused a 24% loss of CST axons in the dorsal col-
umns of the upper cervical spinal cord relative to shams,
with no difference between vehicle-treated and
NT3-treated rats. Together, the MRI and PKCγ histology
data indicate that there were no confounding pretreatment
differences in mean infarct volumes and that NT3 did not
act as a neuroprotective agent, as expected, based on our
previous results16 and given that treatment was initiated
after the majority of cell death would have occurred.
Delayed NT3 Improved Forelimb Sensory and
Motor Function after Stroke
An adhesive patch was attached to each wrist of the rat,
and the order of their removal was noted. From trial to
trial, the size of the patch was progressively increased on
the affected wrist and decreased on the less affected wrist
by an equal amount (see Fig 2A), until the rat removed
the patch on the affected wrist first. A high score (eg, 6)
denotes a deficit (ie, that a rat preferentially removed the
smaller stimulus from their less-affected wrist). The
2 stroke groups exhibited a similar lack of responsiveness
to stimuli on their affected wrist after 1 week (see Fig 2B),
and NT3 enhanced recovery compared to vehicle. Thus,
NT3 improved responsiveness to tactile stimuli after
stroke.
Walking was assessed using a horizontal ladder with
irregularly spaced rungs (see Fig 2C). Accurate paw place-
ment during crossing requires proprioceptive feedback
from muscle spindles.20 After 1 week, the 2 stroke groups
made a similar number of errors with their affected fore-
limb (see Fig 2D). NT3 caused a progressive recovery after
stroke relative to vehicle-treated animals. This is consistent
with previous experiments from our laboratory.14,16 Stroke
also caused modest long-lasting hindlimb deficits on the
ladder; infusion of NT3 into the forelimb triceps brachii
did not improve hindlimb movements (data in archive27).
NT3 also restored the use of the affected forelimb
for lateral support when rats reared in a vertical cylinder
(see Fig 2E). After stroke and vehicle treatment, rats used
their affected forelimb less often than shams. NT3-treated
rats showed more frequent use of the affected forelimb rel-
ative to vehicle-treated rats (see Fig 2F). Stroke caused
transient weakness in forelimb grip strength in both
groups, but infusion of NT3 into triceps brachii did not
modify grip strength (data in archive27).
In summary, infusion of NT3 protein into the tri-
ceps brachii induced recovery on both sensory and motor
tasks that require control of muscles by pathways includ-
ing CSTs, serotonergic raphespinal pathways, and proprio-
ceptive circuits. Accordingly, we hypothesized that NT3
would induce neuroplasticity in multiple pathways.
NT3 Induced Neuroplasticity in Multiple Spinal
Locomotor Pathways
We examined neuroplasticity in the C7 cervical spinal
cord because we knew from experiments using adult and
elderly rats that the less-affected CST sprouts at this level
after injection of AAV-NT3 into muscles, including tri-
ceps brachii.16 Anterograde tracing from the less-affected
sensorimotor cortex (see Fig 1B) revealed that NT3 treat-
ment increased sprouting of the CST in the C7 spinal
FIGURE 4: Neurotrophin-3 (NT3) treatment caused plasticity of serotonergic axons in the C7 spinal cord. (A) The total length of
serotonergic arbors was measured in 3 regions (DH = dorsal horn; IM = intermediate horn; V = ventral horn) on the treated side
relative to the opposite hemicord. (B) NT3 treatment did not increase serotonergic (5HT) arbor length in the dorsal horn or (C) the
intermediate zone but (D) did increase serotonergic arbor length in the ventral horn relative to vehicle (1-way analysis of variance
F2, 22 = 3.5, p = 0.05; Bonferroni post hoc test p = 0.025). *p ≤ 0.05. [Color figure can be viewed at www.annalsofneurology.org]
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cord (see Fig 3A, B) across the midline and into the
affected side at 2 more lateral planes, and also from the
ventral CST.
We assessed neural output in the ulnar nerve on the
affected side, whose motor neurons are also found in C7
(range: C4–C8) and which supply muscles in the forearm,
including the hand.37 To do this, we recorded responses
during electrical stimulation of either the less-affected
CST or the partially ablated CST in the medullary pyra-
mids. NT3 treatment led to enhanced responses in the
ulnar nerve during stimulation of the less-affected and
more-affected pathways (see Fig 3). This result is consis-
tent with the sprouting of traced CST axons at C7 (see
Fig 3A, B) and indicates that CST axons from both the
stroke hemisphere and the contralesional hemisphere
strengthened connectivity to the cord on the treated side,
most likely on premotor interneurons that lie between
CST axons and motoneurons. We also found that NT3
treatment caused serotonergic axons to sprout in the
ventral C7 spinal cord (see Fig 4). Anatomical and
functional plasticity of corticospinal and serotonergic
pathways is consistent with their expression of receptors
for NT3.2,3
We conclude that NT3 caused neuroplasticity in
multiple descending locomotor pathways. These data are
consistent with our findings14,16 that intramuscular AAV-
NT3 can, directly or indirectly, enhance spinal plasticity
after stroke. Next, we assessed the biodistribution of NT3
after peripheral administration.
NT3 Enters the PNS and CNS after Peripheral
Administration
ELISA revealed an increase in total NT3 protein levels in
the triceps brachii on the treated side (Fig 5A) and, sur-
prisingly, on the untreated side (likely due to
NT3 secreted into the bloodstream and taken up by endo-
thelial cells; see below). We were not able to detect any
small increases in exogenous human NT3 against the
background of endogenous rat NT3 in the C7 spinal cord
(data in archive27), because the amino acid sequences for
mature human and rat NT3 are identical.38 Accordingly,
we next used a more sensitive method for measuring traf-
ficking of exogenous NT3 across the blood–CNS barrier.
Radiolabeled NT3 was injected intravenously into
adult mice. Radiolabeled albumin was used as a control,
because it does not enter the CNS efficiently from the
bloodstream. After 3, 15, 20, 30, 40, 60, or 90 minutes,
brain, spinal cord, and serum were taken for scintillation
counting. [3H]NT3 progressively accumulated in the
intact brain and cervical spinal cord (see Fig 5). In plasma,
the half-life of NT3 was short. Our data are consistent
with those of others22–24; for example, after injection of
radiolabeled NT3 into the brachial vein (which provides
drainage from the triceps brachii), NT3 accumulates in
the cortex, striatum, brainstem, cerebellum, spinal cord,
and sciatic nerve, although the majority of NT3 is cleared
rapidly from the bloodstream.22,23 Moreover, the blood–
nerve barrier in DRGs is fenestrated and permeable to
proteins like NT3.39
Next, [3H]NT3 or [3H]albumin was injected intra-
venously into adult mice 24 hours after cortical ischemia.
Forty minutes later, tissues were taken for scintillation
counting. Again, [3H]NT3 accumulated in the brain (see
Fig 5E). To confirm entry of [3H]NT3 into brain paren-
chyma beyond endothelial cells, capillaries were depleted
by gradient centrifugation to yield a fraction containing
brain parenchyma and an endothelial cell–enriched pellet.
[3H]NT3 entered parenchyma (depleted of endothelial
cells) at a level above that seen for [3H]albumin (see
Fig 5F). Transport of NT3 into the CNS is apparently a
receptor-mediated process.6,40
We conclude that neuroplasticity occurred in multi-
ple locomotor pathways because peripherally administered
NT3 bound to receptors in the PNS and CNS.
Blood Oxygenation Level–Dependent Signal in
Perilesional Somatosensory Cortex Evoked by
Stimulation of the Affected Wrist Recovers with
Time after Stroke and Is Not Further Enhanced
by NT3
To explore the mechanism whereby NT3 improved respon-
siveness to stimuli attached to the affected wrist (see Fig 2B),
we performed blood oxygenation level–dependent (BOLD)-
fMRI during low intensity (non-noxious) electrical stimula-
tion of the affected wrist (Fig 6). As expected, prior to stroke,
stimulation of the wrist resulted in a higher probability of
activation of the opposite somatosensory cortex. One week
after stroke, somatosensory cortex was not active when the
affected paw was stimulated in either vehicle-treated or
NT3-treated rats (p values >0.05). fMRI performed 8 weeks
after stroke revealed a trend toward perilesional reactivation
of somatosensory cortex in both vehicle-treated and
NT3-treated groups (p values <0.05). However, these proba-
bilities of reactivation were not big enough to survive correc-
tion for testing of multiple voxels (threshold = 0.01).
A longitudinal analysis showed that at 8 weeks, there
was some evidence that rats treated with NT3 showed
increased probability of activation of perilesional cortex
(p values <0.05; see Fig 6D) and showed decreased proba-
bility of activation of cortex in the less-affected hemi-
sphere (p values <0.05) relative to vehicle-treated stroke
rats. However, these apparent differences did not survive
correction for testing of multiple voxels (threshold = 0.01).
We conclude that both groups showed partial,
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spontaneous restoration of more-normal patterns of
somatosensory cortex activation41 but, conservatively, that
NT3 did not further increase probability of activation of
any supraspinal areas. These conclusions are consistent
with previous fMRI data from our laboratory;16 we pro-
pose that the additional recovery of somatosensory func-
tion after NT3 treatment (see Fig 2B) is due to changes in
the spinal cord rather than in supraspinal areas.
FIGURE 5: Levels of neurotrophin-3 (NT3) were increased in triceps brachii, in brain, and in spinal cord. (A) Enzyme-linked
immunosorbent assay revealed that, in NT3-treated rats, there was an increase in NT3 in the infused triceps brachii (Mann–
Whitney vs vehicle, p = 0.032) as well as in the noninfused triceps brachii (Mann–Whitney vs vehicle, p = 0.032); n = 5 rats/group.
(B) [3H]NT3 entered the brain more abundantly than [3H]albumin. T tests for NT3 versus albumin were all significant for times of
3, 15, 20 30, 40, 60, and 90 minutes (p values from <0.01 to <0.0001), which correspond to “exposure times” up to 450 minutes.
Exposure time is calculated as
Ð
0
tCp(τ)dτ/Cp, where Cp is concentration in plasma and τ is time in minutes. The graph is a Patlak
plot30 showing regression of [3H]NT3 (dark circles and continuous line) and [3H]albumin (light gray circles and dotted line) against
exposure time after intravenous (iv) injection (n = 2–5 mice/time) in adult mice. This corrects for the falling plasma concentration
of solute with real time as shown in D. The volume of distribution (VD) of [
3H]NT3 or [3H]albumin in brain is calculated as a ratio
of counts per minute (CPM) in 1 μg of brain and CPM in 1 μl of serum for each time point and plotted against exposure time
(rather than real time). The rate of influx (Ki) was calculated from the Patlak plot
30 of VD for [
3H]NT3 and [3H]albumin against the
plasma area under the curve. At 1.3×10−5μl/mg/s, the unidirectional influx constant for NT3, Ki, is 100 times that of the albumin
(1.3 × 10−7 μl/mg/s). (C) [3H]NT3 entered the cervical spinal cord more abundantly than [3H]albumin. The graph shows real time
and not exposure time. (D) Plasma half-life of NT3 for the normal adult mouse is ~10 minutes (estimated from 1/normalized
serum values). The graph shows real time and not exposure time. (E) Twenty-four hours after cortical ischemia, [3H]NT3 entered
the brain more abundantly than [3H]albumin, measured 40 minutes after iv injection. (F) Twenty-four hours after cortical
ischemia, levels of [3H]NT3 were higher in parenchyma depleted of endothelial cells than levels of [3H]albumin 40 minutes after iv
injection (parenchyma p < 0.01, capillary fraction p < 0.05, and whole brain p < 0.001, 2-way analysis of variance with Bonferroni
post hoc tests). Results were corrected for the value of VD for
14C sucrose. Number of mice per group is stated on panels.
*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. [Color figure can be viewed at www.annalsofneurology.org]
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FIGURE 6: Functional magnetic resonance imaging during stimulation of the affected wrist revealed increased probability of
perilesional reactivation in both stroke groups but no additional increase by neurotrophin-3 (NT3). The same rats were imaged prior
to stroke and then 1 week and 8 weeks after stroke and intramuscular treatment with either NT3 or vehicle. Scans with obvious
imaging artifacts were discarded, leaving final group numbers of n = 7, 9, and 7 and n = 9, 8, and 4 at weeks 0, 1, and 8 for the
NT3-treated and vehicle-treated groups, respectively. Red voxels denote greater probability of activation during stimulation
(vs stimulation off ), whereas blue voxels denote lesser probability of activation during stimulation (vs stimulation off ). (A) Prior to
stroke, stimulation of the dominant paw led to a strong probability of activation in the opposite somatosensory cortex. (B) One week
after stroke, this activation was abolished by infarction. (C) Eight weeks after stroke, there was a slight trend toward a small
perilesional area of reactivation in both groups. (D) There was a slight trend toward greater perilesional reactivation in the NT3 group
versus the vehicle group at 8 weeks (relative to their baselines). However, all these heat maps of group mean activations show
t values obtained by Statistical Parametric Mapping analysis without correction for multiple testing (p < 0.05) and there were no
differences between the 2 groups for any voxels when the threshold for significance was corrected for multiple testing (p < 0.01;
these data are not shown, as the heat map was black). Red voxels denote greater probability of activation during stimulation for the
NT3 group than for the vehicle group, whereas blue voxels denote lesser probability of activation for the NT3 group than for
the vehicle group. During stimulation of the less-affected wrist, there were no differences between the 2 groups for any voxels when
the threshold for significance was corrected for multiple testing (p < 0.01; these data are not shown, as the heat map was black).
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NT3 Did Not Cause Detectable Hypersensitivity
Finally, we also found no evidence that stroke or NT3
caused hypersensitivity in the forepaw, assessed by applica-
tion of ice-cold acetone (Fig 7). This is consistent with
our previous work showing a lack of mechanical hyperal-
gesia after NT3 treatment,14 with the lack of TrkC on
adult nociceptors,5 and with the human clinical trial data
showing that subcutaneous treatment with NT3 was safe
and well tolerated.25,26
Discussion
Intramuscular infusion of NT3 protein, initiated 24 hours
after stroke, caused changes in multiple locomotor circuits,
and promoted a progressive recovery of sensorimotor func-
tion in rats. That NT3 can reverse disability when treat-
ment is initiated 24 hours after stroke is exciting, because
most stroke victims are diagnosed within this time frame.
NT3 could potentially be used to treat many survivors.
NT3 has good clinical potential. First, phase II clini-
cal trials show that doses up to 150 μg/kg/day are well tol-
erated and safe in healthy humans and in humans with
other conditions.25,26 We used a 3-fold lower dose (48 μg/
kg/day) in this study; in future experiments, we will opti-
mize the dose and duration of treatment, because it is possi-
ble that a higher dose of NT3 would promote additional
recovery. Second, there is conservation from rodents to
humans in the expression of receptors for NT3 in the loco-
motor system.2,3 Third, in none of our rodent experiments
has NT3 treatment caused any detectable hypersensitivity,
spasticity, or muscle weakness; rather, after bilateral CST
injury in rats, intramuscular delivery of AAV-preproNT3
reduced spasms, slightly improved grip strength, and
showed a trend toward reducing mechanical hyperalgesia.14
We used fMRI during electrical stimulation of the
wrist to explore recovery of somatosensory responsiveness
to adhesive patches attached to the wrist. We confirmed
work by others that spontaneous recovery correlated well
with more normal patterns of increased BOLD signal sur-
rounding the infarct41,42 but, as before,16 we did not find
strong evidence that NT3 further increased perilesional
(or other) activation. Accordingly, we propose a different
hypothesis: that NT3 increased somatosensory recovery27
by inducing neuroplasticity in spinal circuits involving
cutaneous afferents. Using a different animal model, we
have previously shown that NT3 normalizes output from
spinal circuits following stimulation of low-threshold affer-
ents from the treated wrist14 (which would activate cuta-
neous afferents as well as proprioceptive afferents, both of
which express receptors for NT35). However, in those
experiments, we measured output in motor axons rather
than sensory output, so in the future one might examine
whether NT3 modulates gating of somatosensory inputs
from the wrist43 after stroke.
With regard to corticospinal neuroplasticity, we have
shown twice previously (in adult and elderly rats) that the
less-affected CST sprouts across the cervical midline into
the affected hemicord after injection of AAV-NT3 into
affected forelimb muscles.16 Others have shown that intra-
thecal infusion of NT3 induces sprouting of the CSTs13
and that injection of vectors encoding NT3 into muscles8
or nerve9 induces CST sprouting after spinal cord injury.
Here, our anatomical tracing confirmed that the less-
affected CST sprouted after infusion of NT3 protein into
triceps, and in future we will trace both CSTs. This is
because, in the present study, neurophysiology revealed
that both CSTs underwent plasticity to the affected side
after unilateral infusion of NT3 protein.
We propose that spared CST axons sprouted after
NT3 entered the CNS from the systemic circulation. This
is consistent with data from us and others showing that
radiolabeled NT3 entered the brain and spinal cord after
intravenous injection.22–24 Moreover, it has been shown
FIGURE 7: Cold allodynia was caused neither by focal cortical stroke nor by treatment with neurotrophin-3 (NT3). The acetone test
was used to determine whether stroke and/or NT3 treatment caused any change in cold allodynia pain responses. The test involves
applying a drop of acetone to the (A) affected or (B) less-affected forelimb, and then allocating a score between 0 and 9; higher
numbers denote a heightened pain response. There is no evidence of painful behavior based on this test in either forelimb. Repeated
measures analysis of covariance was used with Bonferroni post hoc tests. [Color figure can be viewed at www.annalsofneurology.org]
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that endogenous muscle spindle–derived cues induce
sprouting of descending pathways after spinal cord injury
in adult mice20; given that muscle spindles make NT3
endogenously,21 it is plausible that infusion of supplemen-
tary NT3 to muscle might directly enhance CST sprout-
ing after stroke via TrkC receptors on corticospinal
axons.3,44
It is possible, additionally, that NT3 was trafficked
from forelimb muscles in axons to motor neurons and/or
to DRG neurons, where it induced expression of a mole-
cule that was secreted and induced CST sprouting. NT3
is certainly trafficked to ipsilateral motor neurons and
DRGs after intramuscular delivery.4,6,14,16,40 Diffusion
within neuropil is inefficient,45 but spinal motor neuron
dendritic arbors can be very large (some even extend
across the midline46), and these might widely distribute a
cue for supraspinal axonal plasticity (eg, across the mid-
line). In another project, to seek DRG-derived factors,
we have performed RNAseq of cervical DRGs after injec-
tion of AAV-NT3 into forelimb flexors.14,47 In the
future, we will also seek motor neuron–derived cues that
are regulated by NT3.
Unilateral stroke often causes bilateral impairments
in humans and other mammals.48 In principle, intramus-
cular infusion of NT3 into an affected muscle might (after
distribution of NT3 in the bloodstream) enhance sprout-
ing of CST axons to the less-affected side (as well as the
affected side), thereby increasing output to forelimb motor
nerves in the less-affected limb. However, impairments on
the less-affected side are modest and transient in rats with
this model of stroke,27,32 and so any neuroplasticity might
be difficult to detect. It is also notable that infusion of
NT3 into a proximal forelimb extensor improved the
accuracy of use of the affected forelimb during walking on
a horizontal ladder but did not improve the accuracy of
the affected hindlimb (see Duricki et al27); future studies
will determine whether higher doses of circulating NT3
might improve hindlimb movements. Moreover, infusion
of NT3 protein into triceps brachii did not improve fore-
limb grip strength;27 however, the grip strength task prob-
ably depends more on strength in hand and digit flexor
muscles (into which NT3 was not infused) than on triceps
brachii (elbow extensors). Injection of AAV-NT3 into
proximal and distal flexor forelimb muscles does modestly
improve grip strength.14 Taken together, these results
indicate that it may be strategic to target NT3 to multiple
muscles.
Finally, it is encouraging, from a translational per-
spective, that the recovery continues even after infusion of
NT3 is discontinued at 4 weeks. We propose that the
4-week–long NT3 treatment induces changes in target
cells that persist (eg, due to sustained modifications in
gene expression). Longer treatment with NT3 induces dif-
ferent intracellular signaling events in sensory axons than
does brief treatment, thereby enhancing terminal branch-
ing.49 We are currently seeking factors that are persistently
increased in target neurons after NT3 treatment is discon-
tinued. Additionally, it may be that NT3 induces sprout-
ing of CST axons that (after cessation of treatment) is
followed by selection of synapses (eg, strengthening or
pruning) by a mechanism that is independent of NT3.
For example, it is known that corticomotoneuronal axon
synapses are pruned by repulsive PlexinA1–Sema6D inter-
actions.50 To dissect the mechanisms whereby NT3 pro-
motes neuroplasticity and recovery after peripheral
delivery, we have set up a mouse model of stroke.
In summary, treatment of impaired arm muscles
with NT3 (initiated in a clinically feasible time frame)
induces spinal neuroplasticity, improves walking, and
reverses a tactile sensory impairment. Other experimental
therapies that can be delivered with a delay after stroke
include antibodies against Nogo-A, which also induce
neuroplasticity of cortical efferents.51–53 Given the impor-
tance of the CST for spontaneous recovery after stroke,54
these novel strategies offer encouraging prospects for
enhancing neural repair.
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